High-performance liquid chromatographic determination of 9-(3-pyridylmethyl)-9-deazaguanine (BCX-34) in biological fluids

Jieming Yan, Zhihong Lu, Gerald M. Walsh, Richard H. Wheeler, Robert B. Diasio

Research output: Contribution to journalArticle

Abstract

9-(3-Pyridylmethyl)-9-deazaguanine (BCX-34), a new purine nucleoside phosphorylase inhibitor, has selective immunosuppressive activity with potential therapeutic value in T-cell-mediated diseases. We now report a sensitive, specific and reproducible method for measurement of 9-(3-pyridylmethyl)-9-deazaguanine in biological fluids using high-performance liquid chromatography (HPLC). 9-(3-Pyridylmethyl)-9-deazaguanine was extracted from plasma using perchloric acid precipitation followed by passage through Sep-Pak C18 cartridges (average extraction efficiency, 64.6%). Standard curves were linear over the range of interest (28-1120 ng/ml in plasma and 200-4000 ng/ml in urine, r2 > 0.999). Within-day and between-day coefficients of variation were less than 8%. The limit of quantitation was 28 ng/ml in plasma and 200 ng/ml in urine. This HPLC method should be useful in future clinical studies with this drug.

Original languageEnglish (US)
Pages (from-to)295-303
Number of pages9
JournalJournal of Chromatography B: Biomedical Applications
Volume690
Issue number1-2
DOIs
StatePublished - Mar 7 1997

Keywords

  • 9-(3-Pyridylmethyl)-9-deazaguanine

ASJC Scopus subject areas

  • Chemistry(all)

Fingerprint Dive into the research topics of 'High-performance liquid chromatographic determination of 9-(3-pyridylmethyl)-9-deazaguanine (BCX-34) in biological fluids'. Together they form a unique fingerprint.

  • Cite this